It’s been a hot M&A market for biotech companies developing treatments for rare diseases. Nevetheless, Corbus Pharmaceuticals CEO Dr. Yuval Cohen says he is more focused on developing his cystic fibrosis drug Resunab than on deal-making. 'We can certainly choose to partner with a large pharmaceutical company or we can also do it on our own,' says Cohen. 'We have a small, but experienced and nimble team with the resources to take the drug all the way to market.' Resunab is an orally bioavailable synthetic small-molecule designed to naturally switch off heightened inflammation and restore the system to its normal level. The Resunab IND application was approved by the FDA in May and the company is initiating a Phase 2 clinical study for cystic fibrosis which it hopes to begin later this year. Mirroring the volatility in the biotech market this year, shares of the micro-cap company Corbus traded around $3 at last check, up from $2 in February but down from $4 just two weeks ago.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.